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Objective To determine if changes in chromosome 7 and
17 copy number can be used to predict recurrence in
patients with primary noninvasive (pTa) or super-
ficially invasive (pT1) transitional cell carcinoma
(TCC) of the urinary bladder.
Patients and methods Tissue specimens for 129 tumours
from 52 patients (38 men and 14 women) with pTa/
pT1 TCC at first diagnosis were retrieved from
pathology archives. All patient notes were accessed
and disease outcome documented for superficial (pTa/
pT1) recurrence or progression to detrusor muscle
invasion (opT2). The tumours were examined for
chromosomal copy number of chromosomes 7 and 17
using fluorescence in situ hybridization (FISH) with
chromosome-specific probes. The copy number of
chromosomes 7 and 17 was determined in interphase
nuclei on intact 6 mm tissue sections.
Results Aneusomy of chromosomes 7 and 17 was
detected in the index primary tumours of 10 of 32
(31%) patients with subsequent recurrent disease. No
aneusomy for these chromosomes was detected in
primary tumours from 20 patients with no detect-
able recurrence (P = 0.0082). The relative risk of
recurrence was 3.62 times greater (95% confi-
dence interval 1.6–8.1, Cox’s multiple regression
P = 0.0019) for patients with chromosomal aneus-
omy in primary TCC. Neither stage nor grade of the
primary tumours was associated with recurrence in
these patients, nor was there a significant association
with increased grade (G2/3) or stage (opT2) at
recurrence.
Conclusion These results suggest that the measurement
of aneusomy by FISH, using markers for chromosomes
7 and 17, predict recurrence in a subgroup of patients
with pTa/pT1 tumours at presentation. This finding
may offer a new objective and quantitative test for
patients destined to recur.
Keywords Bladder cancer, fluorescence in situ hybrid-
ization, chromosomal aneusomy, recurrence,
prediction
Introduction
We have previously reported that monosomy of
chromosome 9 predicts recurrence of TCC of the
urinary bladder [1]; in the present study, we examined
the role of chromosomes 7 and 17 in predicting TCC
recurrence. About 13 000 new cases of TCC are
reported in the UK each year and the high incidence
of recurrence makes this the second most prevalent
cancer in the UK population. More than 80% of patients
presenting with superficial (pTa/pT1) TCC experience
multiple episodes of tumour recurrence [2,3].
Furthermore, in 10–20% of patients recurrence leads
to progression to detrusor muscle invasion [2,3], with a
reduction in the 5-year survival rate from 95% to 35%
[4,5]. The unpredictable course of TCC and high risk of
recurrence and invasion necessitates intensive monitor-
ing of these patients.
Many genetic lesions have been investigated in TCC
without producing tests of diagnostic value [4–13].
However, earlier studies have suggested that trisomy of
chromosome 7 may be involved in disease recurrence,
whilst polysomy of 17 and loss of heterozygosity (LOH) of
17p have been strongly associated with increased stage
and grade [5,14–17]. This evidence, in conjunction with
our previous experience with chromosome 9 [1], led us to
propose that the use of these markers in primary tumours
might identify patients at risk of recurrence.
Fluorescence in situ hybridization (FISH) has been
widely applied to the study of genetic aberrations in
TCC [15–17]. It is relatively simple, yields valuable
information from intact tissue sections of solid tumours,
and allows the relationship between neoplastic andAccepted for publication 14 July 1999
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non-neoplastic tissue to be studied in situ. In the present
study, FISH was used to quantify aneusomy of chromo-
somes 7 and 17 in TCC, and to identify genetic changes
associated with recurrence.
Patients and methods
Fifty-two patients were selected for this retrospective
study, of whom 51 presented with pTa/pT1 TCC (not
muscle-invasive). One patient presented with carcinoma
in situ (CIS) and subsequently developed TCC. The
patients’ notes were reviewed and patients allocated to
two groups based on their clinical history. Twenty
patients with no recurrence (NR) had one superficial
(pTa/pT1) carcinoma with no subsequent recurrences at
check cystoscopy, and patients with recurrence (REC)
presented with several episodes of recurrent TCC after the
primary carcinoma, either with no evidence of detrusor
muscle-invasive disease (20), or with progression to
muscle invasion during the follow-up (11). Patients
whose primary tumour or first recurrence was treated by
diathermy with no biopsy were excluded. Where
available tumour biopsy material was inadequate to
allow sectioning for study, the patient was also excluded.
Control and tumour material
Morphologically normal, disomic urinary bladder epi-
thelium served as a quality control for the FISH method.
The primary carcinoma, first recurrence and last
documented recurrence (or in patients whose recur-
rences progressed to pT2 and above, that immediately
before and the first muscle-invasive carcinoma) were
analysed by FISH. In some patients the muscle-invasive
carcinoma was obtained at cystectomy. Tumours were
accessed from participating pathology laboratories
(Departments of Pathology at Glasgow and Edinburgh
Royal Infirmaries) and 6 mm serial sections of formalin-
fixed paraffin wax-embedded sections were cut onto 3-
aminopropyltriethoxysilane-treated slides. All tumours
analysed had a representative section stained with
haematoxylin and eosin (H&E), and were re-staged and
re-graded by a specialist urological pathologist (K.M.G.)
following the UICC 1978 guidelines [18].
Fluorescence in situ hybridization
Dual-target FISH was performed with a-satellite repeat
sequence DNA probes for chromosomes 7 and 17, based
on the protocol of Murphy et al. [19]. Briefly the tissue
sections were dried at 56uC, dewaxed, rehydrated and
air-dried immediately before use. Pepsin digestion (0.4%
pepsin, Sigma, Poole, UK, in 0.2 mol/L HCl), to reverse
the protein cross-linking caused by formalin fixation, was
performed at 37uC for 45 min and the pepsin refreshed
after 30 min. Sections were washed five times in distilled
water and dehydrated. To assess the extent of pepsin
digestion, nuclei were stained with 2 mg/mL of 4,6-
diamidino-2 phenylindole-2 hydrochloride (DAPI) in
anti-fade mounting medium (Vectashield, Vectorlabs,
Peterborough, UK). Samples with residual protein mask-
ing nuclei (under-digested) were re-digested as appro-
priate, for a maximum of a further 15 min. Tissue
showing loss of nuclear boundaries (over-digestion) was
discarded and duplicate slides digested for 30 min. Slides
were rinsed in 2rSSC, where SSC was 0.15 mol/L
sodium chloride and 0.015 mol/L sodium citrate,
pH 7.0, and post-fixed in Streck tissue fixative (Alpha
Labs, Eastleigh, UK) for 10 min, dehydrated and air-
dried. Equal volumes of digoxigenin-labelled chromo-
some 7 and biotin-labelled chromosome 17 (Oncor,
Watford, UK) probes diluted 1 : 10 in hybridization
mixture containing 50% formamide, 2rSSC, 0.5 mg/mL
salmon sperm DNA, 2% dextran sulphate (all from
Sigma), giving a final probe concentration of 10 ng/mL,
were applied to the tissue sections on glass coverslips and
sealed with rubber cement. Tissue and probe were
simultaneously denatured on a Misha unit (Shandon
Scientific, Runcorn, UK) for 5 min at 72uC and
hybridized overnight at 37uC. Post-hybridization
washes in 50% formamide, 1rSSC and 2rSSC,
respectively, were conducted at 42uC for 20 min each.
Before immunocytochemical detection, slides were placed
in phosphate buffer, pH 8.0, 0.05% Tween (PNT) and
nonspecific tissue binding blocked in PNTB (PNT and
0.5% Boehringer blocking agent). For two-colour FISH,
the first detection layer was sheep antidigoxigenin (1 mg/
mL, Boehringer, Lewes, UK); slides were then rinsed in
PNT, blocked in 4rSSC, 0.05% Tween and 0.5%
blocking agent (4rSSCTB). Subsequent detection
layers consisted of fluorescein isothiocyanate (FITC)
avidin (25 mg/mL, Vectorlabs) and rabbit antisheep Fab
fragments (18 mg/mL, Stratech, Luton, UK), biotinylated
goat anti-avidin (5 mg/mL, Vector Labs) and Cy3 donkey
antirabbit (3 mg/mL, Stratech), and finally FITC avidin
(25 mg/mL) all diluted in 4rSSCTB. Finally, slides were
mounted in Vectashield containing 2 mg/mL DAPI. This
protocol yielded results of equal colour intensity for both
probes and that were easily quantifiable (Fig. 1).
Evaluation
The signals were visualized using an epifluorescence
microscope (DMLB, Leica, Cambridge, UK), with a 100-W
mercury arc lamp, and photomicrographs taken using a
Wild 48/52 photoautomat system (Leica). Regions for
analysis by FISH were identified by examining H&E-
stained slides and areas to be scored marked on an
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enlarged photocopy (200%) of the section. The number of
signals (range 0–8) for each chromosome in at least 200
non-overlapping nuclei in the control (normal uro-
thelium) and carcinoma sections were counted using a
multichannel counter and recorded. One to three tumour
areas were analysed, a proportion of these by three
independent observers.
The mean chromosomal copy number (MCCN, the
total number of hybridization signals divided by the total
number of nuclei) was used as a measure of overall
chromosomal copy number. Monosomy was assessed
following the parameters previously defined [1]. Normal
ranges for MCCN and monosomy were defined as the
mean 3 SD of values for control normal urothelium.
Aneusomy was defined as tumours with o10% of cells
with three or more signals per nucleus [19,20]. The
mean chromosome counts from each tumour area were
used to give an overall value for each tumour.
Mann–Whitney tests were used to compare differences
in the number of cystoscopies and length of follow-up
between patient groups, and ANOVA to compare age at
diagnosis. The chi-squared and Fisher’s exact tests (where
expected counts were<5) were used to compare stage and
grade at diagnosis, and sex ratios between patient groups,
and to compare aneusomy/normosomy and with stage
and grade. Kaplan-Meier regression analyses were used to
predict recurrence. Cox’s multiple regression analysis was
applied to determine the significance of stage, grade and
aneusomy in predicting recurrence.
Results
For primary tumours, there were no significant differ-
ences in M : F ratios (P = 0.21), mean age at diagnosis
(P = 0.83), length of follow-up (P = 0.53) and number
of cystoscopies (P = 0.95), nor were there significant
differences in stage (P = 0.17) and grade (P = 0.18)
between the patient groups (Table 1). One patient in the
NR group was re-staged by the reference pathologist as a
pT2 tumour. One patient’s primary event in the REC
group was reported as a CIS, another as dysplasia. A
further 77 tumours were analysed from patients in the
REC group, of which 52 (68%) were pTa/pT1, 21 (27%)
were opT2, 27 (35%) were G1 and 46 (60%) were G2 or
G3. Two tumours were classed at pTxGx, one as
dysplastic and one as CIS.
Fluorescent in situ hybridization
Areas from 42 tumours were assessed by three
independent observers (35 by observers A and B, and
a
b
Fig. 1.Photomicrographs of FISH on sections of: A, a disomic bladder
tumour. DAPI-stained nuclei (blue fluorescence) show two copies of
chromosome 7 (Cy3, red) and chromosome 17 (FITC, green). B, an
aneusomic TCC; several copies of chromosomes 7 (red) and 17
(green) represent aneusomy.
Table 1 The demographics of the patients with no recurrence (NR)
or recurrence (REC). One patient’s primary event was reported as
CIS and another as dysplasia. There were no significant differences
in any category between the groups
Group NR REC
Number 20 32
Mean (SD) age at diagnosis, years 67.39 (8.87) 68.06 (11.36)
Sex (M : F) 16 : 4 22 : 10
Median (range) follow-up (months) 50.0 (7–151) 45.5 (2–151)
Median (range) no. of cystoscopies 6.5 (1–14) 6.0 (1–27)
Stage at diagnosis, n (%)
pTa 14 (70) 18 (56)
pT1 5 (25) 12 (38)
pT2/2+ 1 (5) 0
Grade at diagnosis
1 6 (30) 12 (38)
2 12 (60) 13 (41)
3 2 (10) 5 (16)
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seven by observers A and C) to determine the re-
producibility of the results; there was close concordance
among observers. The mean inter-observer variation was
6.70.6% for chromosome 7 and 7.30.8% for chromo-
some 17 copy numbers.
The MCCN was 1.630.07 and 1.610.08 for
chromosomes 7 and 17, respectively. Values of <1.42
and <1.37 were taken to indicate monosomy for
chromosomes 7 and 17, respectively, and those >1.84
and >1.85, respectively, were defined as aneusomic for 7
and 17. Because of the nuclear truncation inherent in
thin histology sections, disomic tumours had MCCN
values of <2.
Fifty-two primary carcinomas from the two groups of
patients were analysed for abnormalities of either chromo-
somes 7 or 17. Eighteen tumours were G1, of which two
were aneusomic, and 32 tumours were G2/3, of which
seven were aneusomic (P = 0.68). Twenty-eight pTa
tumours were normosomic and four aneusomic, and 13
pT1 were normosomic whilst five were aneusomic
(P = 0.44). One primary tumour reported as dysplasia
was also aneusomic. The primary event reported as CIS
was normosomic for both chromosomes.
Ten of 32 primary (first) tumours (31%) from the REC
group and none of 20 from the NR group had
abnormalities of chromosomes 7 and 17 (P = 0.0082).
Neither stage (P = 0.48) nor grade (P = 0.98) of
the primary tumour were associated with recurrence
in the REC group. By univariate analysis, patients
whose primary tumours showed aneusomy of 7 or
17 had significantly shorter disease-free intervals than
in patients with no chromosomal abnormalities
(P<0.001). On multivariate analysis, recurrence could
be predicted by aneusomy and patients with abnormal-
ities of 7 and/or 17 were 3.62 times more likely to
recur (95% CI, 1.6–8.1; Cox’s multiple regression,
P = 0.0019) than patients with normal copy number
for chromosomes 7 and 17 (Fig. 2).
Recurrent tumours
A further 77 tumours were assessed for abnormalities in
the REC group. Of patients with aneusomy in their
primary (index) tumours, 60% remained aneusomic in
all subsequent tumour events studied. Two patients were
aneusomic in one tumour recurrence only. Following
recurrence, a further three patients had chromosomal
abnormalities which were then consistently recapitulated
in all subsequent tumours analysed from these patients.
A change in grade or stage in subsequent recurrences
was not associated with aneusomy in the primary
tumour. Four of 10 patients with aneusomy in their
primary tumours developed a change in grade, to Grade 2
or 3 (P = 0.28); four of 10 developed a change in stage,
to pT2 and above (P = 0.42). Of 22 normosomic
tumours, 12 (55%) had increased stage and seven
(32%) increased grade.
Comparing aneusomy with stage and grade in all
tumours analysed, overall aneusomy for either chromo-
some 7 or 17 or both were detected in four of 47 (8.5%)
G1 and 37 of 76 (49%) G2/3 tumours (P<0.001),
including both primary and recurrent tumours. Similarly
20 of 101 (20%) pTa/pT1 tumours and 14 of 22 (64%)
pT2+ tumours had aneusomy for either or both
chromosome markers (P<0.001).
Discussion
It could be argued that recurrence is by far the most
significant event in the clinical management of bladder
cancer. The high frequency of recurrence and the
associated increase in risk of progression in patients
presenting with superficial TCC is the underlying reason
for the extremely intensive follow-up required for patients
with TCC. Thus far, predictive markers of recurrence
have not been available. The ability to predict recurrence
would undoubtedly improve treatment options in this
extremely prevalent cancer.
Despite extensive research into genetic alterations in
bladder cancer, and detailed models which link such
changes to tumour initiation and progression, there has
been no concurrent improvement in patient manage-
ment as a result of these investigations. This may partly
be because there has been no investigation of recurrence
as a distinct genetically driven event in bladder cancer.
Aneusomy for chromosomes 7 and 17, as detected by
FISH in the present study in primary TCCs, only occurred
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Fig. 2. The time to recurrence, showing the recurrence-free
intervals for patients with normosomy for both chromosomes 7
and 17 (green) and aneusomy chromosome 7 and/or 17 detected in
primary tumours (red). Vertical lines represent the extent of follow-
up. The relative risk of recurrence (Cox’s multiple regression
analysis) was 3.62 times greater for patients with abnormal
chromosome numbers (P = 0.0019).
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in patients who subsequently developed recurrence.
Aneusomy in primary tumours did not predict an
increase in grade or stage at subsequent recurrence.
Ten of 32 (31%) patients had aneusomy in their primary
tumours. There appears to be a strong association
between aneusomy of these chromosomes and early
recurrent disease (odds ratio 3.62, Cox’s multiple
regression), independent of the known effects of high
(pT1) stage and grade (G2/G3) in predicting recurrence.
This is the second chromosomal marker to be associated
with disease recurrence. Bartlett et al. [1] showed that
monosomy of chromosome 9 in primary tumours from a
similar patient cohort is strongly predictive of disease
recurrence in TCC patients. About 35% of patients in
their study were monosomic for chromosome 9, of whom
91% developed disease recurrence. The possibility that
these markers identify independent genetic routes to
recurrence may allow the identification of the risk of
recurrence in up to two-thirds of patients presenting with
superficial bladder cancer.
At present, frequent cystoscopy is the only means by
which patients can be accurately monitored. This
combined with transurethral resection and, in appro-
priate cases, intravesical chemotherapy, will reduce the
risk of progression to muscle invasion [21]. It has been
suggested that the ability to predict recurrence at
presentation could improve treatment and follow-up of
patients by reducing rates of recurrence by 30% over 5
years [22], but at present it is not possible to accurately
identify patients at high risk of recurrence, and therefore
progression, by cystoscopy and pathology alone. The use
of a diagnostic marker of high risk of recurrence would
improve the treatment and the quality of life in a
significant proportion of patients. This would reduce the
need for frequent attendance at clinic, thereby minimiz-
ing the patients’ stress and anxiety. FISH is an accurate,
reproducible and quality-controlled system for identifying
markers of recurrence in TCC. Intervention in patients at
high risk of recurrence because of tumour aneusomy,
using single or multiple doses of epirubicin, mitomycin C
or intravesical BCG, could significantly reduce recurrence
rates in the population with bladder cancer in the UK.
Neither stage nor grade can be used in a similar way to
predict recurrence. Whilst both increased stage and grade
are associated, both in this study and elsewhere, with
increasing genetic abnormalities, it is striking that in the
primary (first) tumours analysed here, aneusomy pre-
dicted recurrence independently of either grade or stage.
The significant association between aneusomy and
opT2 in all the tumours studied, rather than pTa/1
disease, would not compromise this finding as patients
with detrusor muscle invasion (opT2) are not routinely
left untreated. The association of aneusomy with high
grade supports the clinical observation that high-grade
tumours are more likely to recur, and may provide a
means of identifying those patients with higher grade
disease at greatest risk of recurrence.
The association between aneusomy of chromosomes 7
and 17 in patients at high risk of subsequent recurrence
indicates that genes on these chromosomes promote
recurrence. Changes in p53 expression and subchromo-
somal alterations of chromosome 17 have been linked
with CIS and progression to detrusor muscle invasion by
papillary TCC. In contrast, relatively little is known about
genetic alterations on chromosome 7 and outcome in
TCC. However, studies by Neal et al. [23] have shown
that overexpression of EGFR is a risk factor for recurrence
in TCC. This could be linked to increased copy number of
this gene, which is on chromosome 7. This event may
also be associated with genetic instability [14]. Low-level
amplification of c-erbB2, on chromosome 17, may also
promote recurrence, with subsequent loss of p53 driving
progression events. TP53 mutations are known to
destabilize the genome [4,6] which would allow cells to
gain a more malignant phenotype. Previous reports have
found that both overexpression of c-erbB2 and abnormal
expression of p53 are associated with progression [5–7].
Saran et al. [6] reported that overexpression of EGFR was
associated with high-grade tumours, and Ozen [5]
reported that there was a strong association with high
stage and grade. Ozen [5] suggested that c-erbB2 and
TP53 could be responsible for progression to high grade
and lamina propria invasion. These studies and others
[4,14,24] support the findings of abnormalities in 7 and
17 reported here. However, there have been no studies
associating such changes specifically with recurrence
and it may be dangerous to extrapolate alterations
associated with progression to a separate disease event.
There was a striking concordance in the copy number
of chromosomes 7 and 17 throughout this study, as has
been previously shown for renal cancers [20]. Separate
investigations have shown that these changes occur
independently of polyploidy and can therefore be
regarded as chromosome-specific events [25].
In conclusion, the present results strongly support the
role for genetic analysis in the predictive diagnosis of
disease recurrence in patients with TCC. Such diagnosis
offers significant opportunities for treatment intervention
and improvement of patient outcome. Aneusomy of
chromosomes 7 and 17, occurring in 31% of the present
patients with pTa/pT1 disease at presentation, predicted
recurrence.
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